174 related articles for article (PubMed ID: 9538362)
1. [Aspirin in secondary cardiovascular prevention: from clinical studies to daily practice].
Garnier LF
Ann Cardiol Angeiol (Paris); 1997 Oct; 46(8):507-12. PubMed ID: 9538362
[TBL] [Abstract][Full Text] [Related]
2. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
[TBL] [Abstract][Full Text] [Related]
4. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
5. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
Temizhan A
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
7. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
8. [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].
Di Pasquale G; Ottani F; Ceré E; Biancoli S; Sassone B; Lombardi A
Recenti Prog Med; 1998 Oct; 89(10):514-9. PubMed ID: 9842255
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
[TBL] [Abstract][Full Text] [Related]
10. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Arjomand H; Cohen M; Ezekowitz MD
J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Prescrire Int; 2000 Jun; 9(47):89-90. PubMed ID: 11010752
[TBL] [Abstract][Full Text] [Related]
12. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
13. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
14. Aspirin for the primary prevention of cardiovascular events.
Ferrini R; Clark B
Am Fam Physician; 2002 Nov; 66(9):1737-8. PubMed ID: 12449273
[No Abstract] [Full Text] [Related]
15. Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Mikkelsson J; Eskola M; Nikus K; Karhunen PJ; Niemela K
Ann Med; 2008; 40(4):296-302. PubMed ID: 18428022
[TBL] [Abstract][Full Text] [Related]
16. Aspirin for prevention of myocardial infarction.
Mirvis DM
J Tenn Med Assoc; 1995 Oct; 88(10):392-4. PubMed ID: 7475013
[No Abstract] [Full Text] [Related]
17. Low-dose aspirin for primary prevention of cardiovascular disease.
Bredie SJ; Wollersheim H; Verheugt FW; Thien T
Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
Second Chinese Cardiac Study (CCS-2) Collaborative Group
J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
[TBL] [Abstract][Full Text] [Related]
19. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
20. Aspirin resistance or variable response or both?
Cheng X; Chen WH; Simon DI
Am J Cardiol; 2006 Nov; 98(10A):11N-17N. PubMed ID: 17097412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
